AfriAg Global Plc - Notice of GM for Apollon Formularies Acquisition
PR Newswire
Proposed Appointments and Resignations
General Meeting to Approve the Acquisition of Apollon Formularies Ltd
Posting Admission Document and Notice of General Meeting
Further to previous announcement regarding the proposed reverse take-over of medicinal cannabis company Apollon Formularies Ltd ( Apollon ) (the RTO or the Proposed Acquisition ) on 23 February 2021, AfriAg is pleased to announce today the posting of its admission document and notice of general meeting to be held at 7-9 Swallow Street, London, United Kingdom, W1B 4DE at 10 a.m. (London Time) on 12 April 2021.
As a consequence of COVID-19, the General Meeting will be run as a closed meeting and Shareholders will not be able to attend.
Small Cap Feast - Thor Explorations; Imperial X; Emmerson; Vast Resources; Circle Property proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
AfriAg Global Plc - Result of GM and AQSE Regulatory Approval for Apollon
PR Newswire
( Company )
AQUIS REGULATORY APPROVAL TO ACQUIRE APOLLON
The Company is pleased to announce that at the General Meeting of the Company held today, all resolutions were duly passed. The Company is also pleased to announce that AQSE Regulatory approval to be admitted to the AQSE Growth Market has now been received to acquire the entire issued share capital of Apollon Formularies Limited, and it is expected that admission to trading will commence tomorrow, 13 April 2021 at 8 a.m. The Enlarged Share Capital of 748,376,677 Ordinary Shares will be admitted to trading, comprising 31,710,011 Existing Ordinary Shares, 666,666,666 Consideration Shares and 50,000,000 Placing Shares and Subscription Shares.
AfriAg Global Plc - Posting of Supplementary Admission Document
PR Newswire
Posting of Supplementary Admission Document
The Company announces, further to the announcement of 19 March 2021, a supplementary admission document is being posted to shareholders today.
Pursuant to Apollon s option to acquire 90% of the stock of Doc s Place under a Right to Purchase Understanding ( Doc s Place RPU ), and Apollon s exclusive right to purchase the assets and assume certain liabilities and obligations of CBev under a Right to Purchase Understanding ( CBev RPU ), an additional risk factor is being brought to Shareholder s attention.
A copy of the Chairman s letter, including the additional risk factor, contained in the supplementary admission document, in the event that either the Doc s Place RPU or CBev RPU is triggered, are set out in full below in this announcement without material amendment or adjustment.